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Background: An increased incidence of Achromobacter xylosoxidans infections has been observed at the Cystic Fibrosis Centre at Aarhus
University Hospital, as the proportion of patients colonised with A. xylosoxidans increased from 6 to 10% from 2005 to 2009.
Methods: Pulsed field gel electrophoresis (PFGE) was used to type isolates of A. xylosoxidans.
Results: Four patients infected for 2–7 years were part of a larger epidemic spread involving both Danish CF centres, while 11 patients carried
strains with unique genotypes. Longitudinal analysis of isolates from ten patients with multiple preserved isolates showed that each patient
persistently carried isolates of a single genotype. Following lung transplantation, two patients showed re-colonisation of the lung grafts with the
pre-transplant A. xylosoxidans strain.
Conclusions: A. xylosoxidans has been transmitted between patients from our clinic, but the recent increase in incidence is not caused by cross
infections.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Achromobacter xylosoxidans; Cystic fibrosis; Cross infection1. Introduction
Lung infections with bacteria such as Haemophilus influen-
zae, Staphylococcus aureus, Pseudomonas aeruginosa, and
Burkholderia cepacia complex are a major cause of morbidity
and mortality in cystic fibrosis (CF) patients [2,3]. Other
potentially pathogenic bacteria are identified with increasing
frequency in CF patients, includingAchromobacter xylosoxidans,
Stenotrophomonas maltophilia, Ralstonia sp., Pandorea sp., and
Inquilinus limosus[2]. An increased prevalence of infections and
colonisations with A. xylosoxidans has been observed in recent
years, with reports of prevalence as high as 29% in some centres☆ Data was presented at the 33rd European Cystic Fibrosis Conference in Valencia
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doi:10.1016/j.jcf.2011.07.004[4]. Strains of A. xylosoxidans are innately resistant to many
antibiotics and may develop resistance to virtually all available
antibiotics [5]. The clinical significance of infection with A.
xylosoxidans in CF patients is not fully elucidated. While some
patients may be asymptomatically colonised for prolonged
periods of time, others experience rapid deterioration of lung
function following infection [6,7]. In this report, the terms
colonisation and infection are used interchangeablywithout direct
reference to the clinical course of individual patients.
Several reports document the occurrence of person-to-person
transmission of A. xylosoxidans[4,7–12]. A. xylosoxidans is able
to establish chronic infection in CF patients, but whether patients, Spain on 17 June 2010, and is published as an abstract in J. Cystic Fibrosis [1 ].
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co-exist or displace each other, is disputed [4,9–12].
At Aarhus University Hospital the proportion of CF patients
with at least one airway sample positive for A. xylosoxidans
during a calendar year has increased from 6% in 2005 to 10% in
2009, with five patients experiencing a first-time isolation of
A. xylosoxidans in 2009. The aim of this study is to investigate
the possible occurrence of cross infections in our clinic, and to
appraise the question of strain displacement in CF patients with
long-term A. xylosoxidans colonisation.2. Methods
One hundred and fifty-one isolates of A. xylosoxidans were
analysed (Table 1). The specific identification of isolates
included in the study was confirmed by Matrix-assisted laser
desorption/ionisation time-of-flight analysis (MALDI Biotyper,
Bruker).
Pulsed field gel electrophoresis (PFGE) was performed as
described by Turabelidze et al. [13]. Isolates were analysed in
duplicate using restriction enzymes XbaI and SpeI. Electropho-
resis was carried out for 22 h at 6 V/cm, with pulse-times ranging
from 5 s to 35 s using the CHEF-DR® II system (Bio-Rad).
Restriction patterns were interpreted according to the criteria of
Tenover et al. [14].
3. Results
A. xylosoxidans was isolated from 15 of 143 (10%) CF
patients from the centre at Aarhus University Hospital during
2009. Five patients had been infected for more than six years,
five patients had been infected for two to three years, and fiveTable 1









Study I Study II Study III
1 1995 17 + 16
2 1996 11 + + 8
3 2002 13 +✶ + 22
4 2002 12 + + 21
5 2002 12 + 5
6 2003 15 +✶ + 22
7 2003 25 + + 5
8 2004 14 +✶ + 22
9 2007 19 +✶ + 11
10 2007 19 + + 11
11 2007 21 + 1
12 2008 33 + 1
13 2008 16 + 1
14 2009 17 + 1
15 2009 23 + 1
16 2009 23 + 1
17 2009 13 + 1
18 2009 6 + 1
Ax, A. xylosoxidans; Study I, comparison of isolates from 2009; Study II,
longitudinal study of colonisation dynamics; Study III, comparison of pre- and
post-transplant isolates. *, identical PFGE profiles.patients experienced a first-time identification of A. xylosox-
idans in their respiratory cultures during 2009 (Table 1). To
investigate whether the conspicuous number of new acquisi-
tions was caused by cross infections, one isolate from all 15
patients with positive cultures during 2009 was subjected to
PFGE analysis. Restriction patterns obtained with each of the
enzymes XbaI and SpeI were similar, and showed that four of
the patients carry A. xylosoxidanswith identical macro restriction
patterns. These four patients have been colonised with
A. xylosoxidans since 2002, 2003, 2004, and 2007, respectively
(Table 1). The remaining 11 patients, including all patients with a
first-time identification of A. xylosoxidans during 2009, carry
strains with unique PFGE profiles (Fig. 1).
To investigate whether patients were colonised with more than
one strain, ten patients with multiple preserved isolates of
A. xylosoxidans were selected (Table 1). The patients had been
colonised with A. xylosoxidans for three to thirteen years. A total
of 142 isolates, with 5 to 22 isolates per patient collected during
three to eight years, were subjected to PFGE analysis. For all
patients, a single, persistent clone was detected throughout the
study period (representative gel from one patient is shown in
Fig. 2).
Two lung transplanted patients showed re-colonisation of the
lung grafts with the pre-transplant A. xylosoxidans strain, as
determined by PFGE analysis: One CF patient had bilateral lung
transplantation in 2005, after being colonised with
A. xylosoxidans for one year prior to transplantation. Two
weeks after transplantation A. xylosoxidans was cultured from
airway secretions obtained by broncho-alveolar lavage (BAL),
and after one year A. xylosoxidans was isolated regularly from
sputum. Isolates obtained before and after lung transplantation are
identical by PFGE analysis (Fig. 3A). A second patient had
bilateral lung transplantation in 2006 after being colonised with
Pseudomonas aeruginosa for six years, and with A. xylosoxidansFig. 1. Pulsed field gel electrophoresis of SpeI digested genomic DNA from 15
isolates of A. xylosoxidans collected during 2009 from 15 CF patients. Five
patients had been infected for more than six years (a–e), five patients had been
infected for two to three years (f–j), and five patients experienced a first-time
identification of A. xylosoxidans in 2009 (k–o). Four patients carry strains with
identical macro restriction profiles (c–f). Lanes M: molecular marker.
Fig. 2. Pulsed field gel electrophoresis of SpeI digested genomic DNA from twenty two isolates of A. xylosoxidans cultured from airway secretions from a CF patient
between 2003 and 2009. Lanes 1–2: 2003, 3–6: 2005, 7–10: 2006, 11–14: 2007, 15–18: 2008, 19–22: 2009. Lanes M: molecular marker.
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was recovered from BAL specimens, and after 12 months
A. xylosoxidans was isolated from BAL specimens. Four years
post-transplantation, P. aeruginosa is regularly cultured from
sputum, while A. xylosoxidans has only been detected on three
occasions, and only from BAL. PFGE analysis shows that the
post-transplant strain is identical to the isolates obtained before
lung transplantation (Fig. 3B).
4. Discussion
The CF clinic at Aarhus University Hospital has seen a marked
increase in the incidence of A. xylosoxidans during 2009. In order
to evaluate if the unexpected number of new cases could be due to
cross infections, we compared one isolate from all patients
experiencing a positive culture with A. xylosoxidans during 2009.
Four of 15 patients were colonised with isolates of the same
genotype of A. xylosoxidans. These patients are part of a larger
outbreak that has affected five patients from our centre and eight
patients from the Copenhagen CF centre [7]. The patients from ourFig. 3. Pulsed field gel electrophoresis of SpeI digested genomic DNA from iso
transplantation in 2005. B. Isolates from a CF patient who underwent lung transplanclinic that carry the epidemic clone are known to have had close
social contact, including participation in winter camps for CF
patients from both centres. The observed spread between clinics
indicates close social contact as mode of transmission, although,
secondary spread within the clinics cannot be excluded. As part of
the infection control policy of the clinic, staff and patients have
been rigorously instructed in correct hand- and coughing-hygiene;
the out-patient clinic runs with one line only, thereby minimising
the number of patients at any one time in the clinic; the in-patient
rooms are predominantly single room, or, rarely, two-patient
rooms shared with a non-CF patient. After implementing cohort
segregation policies for patients with A. xylosoxidans and
discouraging social contacts between infected and uninfected
patients, the spread of the Danish epidemic clone has ceased. A
single patient was infected with the clone after introduction of the
segregation policy (patient no. 9). This patient has continued close
social contact with two patients from the A. xylosoxidans cluster,
suggesting transmission outside the CF centre. Interestingly, a
similar epidemic spread occurredwithP. apista[15], butwas never
observedwithB. cepacia complex amongDanishCF patients [16].lates of A. xylosoxidans. A. Isolates from a CF patient who underwent lung
tation in 2006. Lanes M: molecular marker.
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including the five incident cases, all carry strains with unique
genotypes. Our findings confirm that A. xylosoxidans is able to
cross infect CF patients, in agreement with previous reports [4,7–
12]. However, the increased prevalence of A. xylosoxidans in our
clinic during 2009 is not caused by person-to-person transmis-
sion, but reflects the sporadic acquisition of A. xylosoxidans from
the environment. Very little is known of the factors governing the
sporadic acquisition of A. xylosoxidans, and more studies are
clearly needed to elucidate this.
To address the question of strain displacement we typed
multiple isolates of A. xylosoxidans cultured from individual
patients during periods of three to eight years.We found that each
of the ten patients persistently carried a genetically indistinguish-
able strain of A. xylosoxidans. This finding is in agreement with
the studies of Kanellopoulou et al. [11] and Lambiase et al. [10],
while others have reported that CF patients may be infected with
multiple strains [4,9,12]; in these latter studies, however, a single
strainwith amarkedly different genotypewas disclosed only once
in patients with multiple detections of a dominating strain. Such
singular findings may be explained by transient colonisation, or
possibly by sample mix-ups or misidentifications of bacteria in
the laboratory, and do not represent strain displacements or
genuine concomitant infections with multiple strains.
Two patients with lung transplants were re-colonised with the
pre-transplant A. xylosoxidans strain (Fig. 3). Whereas re-
colonisation with P. aeruginosa after lung transplantation is
well known [17], re-colonisation with A. xylosoxidans has, to our
knowledge, not been described previously. It has been speculated
that the sinuses act as a reservoir from which bacteria can spread
to the lungs, and some CF centres recommend surgical drainage
of the sinuses prior to lung transplantation [18,19].
In conclusion, our studies confirm that A. xylosoxidans is able
to cross infect CF patients. Segregation policies effectively restrict
person-to-person transmission; however, incidence rates may
increase due to sporadic acquisition of A. xylosoxidans from the
environment. Patients with long-term colonisations persistently
carry a single clone of A. xylosoxidans that may re-colonise lung
grafts following transplantation.
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